| abstract |
3- (2,4-bis (trifluoromethyl) benzyloxy) phenylacetic acid, 4- (2,6-dimethylbenzyloxy) -phenylacetic acid, and pharmaceutically acceptable salts thereof are insulin resistance syndrome, It is useful for the treatment of various metabolic abnormalities such as diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis. The bioactive agents of the present invention that have been tested are established animal models of human diabetes and insulin resistance syndrome. Activity was demonstrated in the bioactivity assay described below. All bioactive agents of the present invention are also believed to have activity in one or more of these assays. Such agents would therefore be effective in the treatment of diabetes and insulin resistance syndrome. |